The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer

Part of paid clinical trials in Norwalk, Connecticut.

Sponsor
Nuvance Health
Study ID
NCT04406831
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Blood draw — PROCEDURE
    Individuals in the unresectable pancreatic cancer group will receive monthly blood draws. Individuals in the control group will receive one blood draw

Study Details

Aberrant miRNA production has been linked to a wide range of human cancers and shown to play important roles in their genesis and growth. These miRNA can be detected in the blood and tumors of patients with cancer. The investigators hypothesize that the detection of certain miRNAs present in the blood/serum of patients with pancreatic cancer may be important to the early diagnosis of the disease. Furthermore, the investigators hypothesize that miRNA detection in PC patients will yield prognostic information and help predict the response to treatment.

Key Dates

Start date
Apr 30, 2015
Status verified
Apr 2026
Primary completion
Apr 30, 2030
Completion
Apr 30, 2030

Study Design

Enrollment
200 participants (estimated)

Arms

  • Arm: New Unresectable Pancreatic Cancer
    Individuals with biopsy-proven adenocarcinoma of the pancreas, classified as locally advanced or metastatic disease
  • Arm: Control
    Healthy individuals without cancer diagnoses to provide reference microRNA

Primary Outcome Measure

Analysis of miRNA profile [ Time Frame: Through study completion, up to 5 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Nuvance HealthNorwalkConnecticut06856
Tammy Lo, APRN
[email protected]
203-855-3551
Richard Frank, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Norwalk, CT

By condition
Pancreatic cancer
By specialty
OncologyGI oncology
By research site
Nuvance Health· Norwalk, CT

Related Studies